All Weight Loss Programs
We have several options to help you with your metabolic reset, all online
WAYT-LESS
WAYT-less® is our new and improved weight-loss program!
WAYT-TAIN
WAYT-tain® is our new and improved maintain program!
DIET GUIDELINES
The WAYT-less ® Diet E-book grants you access to many practical and delicious recipes for your diet!
ULTRA BURN
Enhance your body’s natural fat-burning abilities!
B12 INJECTIONS
Increase Your Energy Levels & Improve Your Brain Performance!
New Article Puts Acarbose Back on the Stage
Medically reviewed by
Dr. Constance Odom, MD
About
Constance Tambakis Odom, MD graduated in 1987 with her Doctorate of Medicine from the New York Medical College, and was an Anesthesiologist Resident from 1988 to 1991 at the Brookdale Medical Center PGY II (CA-I)-PGY IV (CA-III). She is Board Certified by the American Board of Anesthesiology since 1998 and American Academy of Anti-Aging Medicine since 2002. Constance Odom, MD is affiliated with the American Medical Association, American Academy of Anti-Aging Medicine, American Society of Anesthesiology, Georgia Society of Anesthesiology, Hellenic Medical Society of New York, North Carolina Society of Anesthesiology, and Society of Ambulatory Anesthesia.
Credentials
Medical Director At:
- Nu Image Medical
- MetroMedispa P.A.
Staff Anesthesiologist at:
- Betsy Johnson Regional Hospital in Dunn, NC
- Onslow Memorial Hospital in Jacksonville, NC
- Duplin General Hospital in Kenansville, NC
Director of Anesthesia Services at:
- Jacksonville Surgery Center in Jacksonville, NC
A new article by Mustafa Altay, Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Keçiören Health Administration and Research Center, Keçiören 06290, Ankara, Turkey, discusses about acarbose an agent that has been used to treat type 2 diabetes for about 30 years
The article highlights the findings of a study conducted by Song et al on the effect of acarbose on abdominal obesity in comparison to metformin as a treatment for type 2 diabetes mellitus. The study found that acarbose treatment was as effective and safe as metformin at the 24th and 48th weeks. The authors also noted a relationship between high waist-to-height ratio and treatment with acarbose with gender, GLP-1 level, fasting glucose, and lipid profile. Additionally, the study found that acarbose reduced the risk of cardiovascular events and all-cause mortality in patients with type 2 diabetes mellitus.
The article also discusses the role of acarbose in the treatment of diabetes and its recent resurgence in importance. The STOP-NIDDM and ACE studies found that acarbose prevents the development of diabetes regardless of age, gender, and body mass index, and reduces cardiovascular events in patients with impaired glucose tolerance and type 2 diabetes mellitus. Furthermore, acarbose has been found to reduce oxidative stress and quickly provide joint target controls. The article notes, however, that some studies were conducted only in Chinese patients, limiting their generalizability.
Overall, the article suggests that acarbose should continue to be considered as a viable treatment option for patients with type 2 diabetes mellitus and impaired glucose tolerance, and its mechanisms of action should be further explored.
This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. Always talk to your physician about the risks and benefits of any treatment. Nu Image Medical may not offer the medications or services mentioned in this article.